Soluble complement receptor 1: TCEL and SmithKline Beecham agreed to close the initial Phase I trial of sCR1 conducted by SmithKline in burn patients at risk of

The trial will be unblinded and data analyzed and used to provide initial safety and pharmacokinetic

Read the full 166 word article

How to gain access

Continue reading with a
two-week free trial.